Wall Street Analysts See a 64.09 percent Upside in Monte Rosa Therapeutics Can the Stock Really Move This High?
GLUE Stock | USD 8.51 0.93 9.85% |
About 66% of Monte Rosa's investor base is looking to short. The analysis of the overall investor sentiment regarding Monte Rosa Therapeutics suggests that many traders are alarmed. The current market sentiment, together with Monte Rosa's historical and current headlines, can help investors time the market. In addition, many technical investors use Monte Rosa Therapeutics stock news signals to limit their universe of possible portfolio assets.
Monte |
The mean of analysts price targets for Monte Rosa Therapeutics points to a 64.1 percent upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read at finance.yahoo.com
Monte Rosa Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Monte Rosa can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Monte Rosa Fundamental Analysis
We analyze Monte Rosa's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Monte Rosa using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Monte Rosa based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Debt
Total Debt Comparative Analysis
Monte Rosa is currently under evaluation in total debt category among its peers. Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Monte Rosa Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Monte Rosa stock to make a market-neutral strategy. Peer analysis of Monte Rosa could also be used in its relative valuation, which is a method of valuing Monte Rosa by comparing valuation metrics with similar companies.
Peers
Monte Rosa Related Equities
DSGN | Design Therapeutics | 4.23 | ||||
STTK | Shattuck Labs | 2.31 | ||||
IKNA | Ikena Oncology | 1.80 | ||||
NKTX | Nkarta | 1.20 | ||||
GBIO | Generation Bio | 0.79 | ||||
KYMR | Kymera Therapeutics | 0.07 | ||||
HOWL | Werewolf Therapeutics | 0.54 | ||||
FHTX | Foghorn Therapeutics | 0.63 | ||||
ERAS | Erasca | 0.67 | ||||
STOK | Stoke Therapeutics | 2.11 | ||||
NRIX | Nurix Therapeutics | 3.40 | ||||
SANA | Sana Biotechnology | 6.42 | ||||
LYEL | Lyell Immunopharma | 7.61 |
Complementary Tools for Monte Stock analysis
When running Monte Rosa's price analysis, check to measure Monte Rosa's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Monte Rosa is operating at the current time. Most of Monte Rosa's value examination focuses on studying past and present price action to predict the probability of Monte Rosa's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Monte Rosa's price. Additionally, you may evaluate how the addition of Monte Rosa to your portfolios can decrease your overall portfolio volatility.
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum |